公开(公告)号：US20240307538A1

公开(公告)日：2024-09-19

申请号：US18551156

申请日：2022-03-18

申请人： UNIVERSITE TOULOUSE III - PAUL SABATIER ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE ,  CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER ,  UNIVERSITE DE MONTPELLIER ,  ARTHRITIS RECHERCHE & DEVELOPPEMENT

发明人： Cyril CLAVEL ,  Guy Bruno René SERRE ,  Pierre MARTINEAU ,  Nerea ALLENDE-VEGA ,  Florence APPARAILLY ,  Martin VILLALBA ,  Christian JORGENSEN

IPC分类号： A61K39/00 ,  C07K14/735 ,  C07K14/75 ,  C12N5/0783 ,  C12N5/0786

CPC分类号： A61K39/46433 ,  A61K39/4613 ,  A61K39/4614 ,  A61K39/4621 ,  C07K14/70535 ,  C07K14/75 ,  C12N5/0645 ,  C12N5/0646 ,  C07K2319/30 ,  C12N2510/00

摘要： The invention relates to an immune cell comprising at least one Fc receptor on its surface, characterised in that a hybrid molecule is grafted onto the Fc receptor, said hybrid molecule comprising at least one antibody Fc fragment covalently bound to at least one fibrin-derived peptide comprising one or more citrullyl residue(s). The present invention also relates to the uses of such a grafted cell, as well as its method of production.

公开(公告)号：US20240238446A1

公开(公告)日：2024-07-18

申请号：US18417702

申请日：2024-01-19

申请人： CAMBRIDGE ENTERPRISE LIMITED ,  THE SYDNEY CHILDREN'S HOSPITALS NETWORK (RANDWICK AND WESTMEAD)

发明人： Peter Lachmann ,  Ian Alexander

IPC分类号： A61K48/00 ,  A61K9/00 ,  A61K35/76 ,  C07K14/75 ,  C12N7/00

CPC分类号： A61K48/0058 ,  A61K9/0019 ,  A61K35/76 ,  C07K14/75 ,  C12N7/00 ,  C12N2750/14123 ,  C12N2750/14133 ,  C12N2750/14143

摘要： Methods of treatment of complement-mediated disorders, in particular disorders associated with over-activity of the complement C3b feedback cycle (for example, age-related macular degeneration (AMI)), using gene therapy is described. According to the methods, levels of complement Factor I are elevated by administration of a recombinant viral vector encoding Factor I such that a therapeutically effective amount of the encoded Factor I is expressed from the vector in the subject. Recombinant viral vectors encoding Factor I, recombinant virus particles encapsidating the vectors, and their use in the methods of treatment, is also described.

公开(公告)号：US12016909B2

公开(公告)日：2024-06-25

申请号：US17236534

申请日：2021-04-21

申请人： EpiVax Inc.

发明人： Anne De Groot ,  William Martin ,  Daniel S. Rivera

IPC分类号： A61K39/00 ,  A61K38/00 ,  C07K14/47 ,  C07K14/75 ,  C07K14/76 ,  C07K14/78 ,  C07K14/79

CPC分类号： A61K39/0008 ,  C07K14/47 ,  C07K14/75 ,  C07K14/76 ,  C07K14/78 ,  C07K14/79 ,  A61K38/00

摘要： The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.

公开(公告)号：US20240199719A1

公开(公告)日：2024-06-20

申请号：US18038541

申请日：2021-08-20

申请人： MIRAKI INNOVATION THINK TANK LLC

发明人： Christopher VELIS ,  Keith CRAWFORD

IPC分类号： C07K14/705 ,  A61K38/00 ,  A61K45/06 ,  C07K14/47 ,  C07K14/75 ,  C07K14/78

CPC分类号： C07K14/70503 ,  A61K45/06 ,  C07K14/47 ,  C07K14/705 ,  C07K14/75 ,  C07K14/78 ,  A61K38/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30

摘要： The present invention provides compositions comprising microbe-targeting molecules (MTMs) that bind microbe-associated molecular patterns, and methods of using the compositions in the prevention and treatment of infectious disease.

公开(公告)号：US20230312678A1

公开(公告)日：2023-10-05

申请号：US18056029

申请日：2022-11-16

申请人： DIADEM BIOTHERAPEUTICS INC.

发明人： Mickey Pentecost ,  Wojciech Bartkowski

IPC分类号： C07K14/705 ,  A61K47/69 ,  A61K47/58 ,  A61K47/62 ,  A61K47/54 ,  A61P27/02 ,  A61P37/06 ,  C12N9/14 ,  C07K14/75

CPC分类号： C07K14/70532 ,  A61K47/6911 ,  A61K47/605 ,  A61K47/62 ,  A61K47/69 ,  A61K47/544 ,  A61K47/6901 ,  A61P27/02 ,  A61P37/06 ,  C07K14/705 ,  C07K14/70521 ,  C07K14/7056 ,  C07K14/70596 ,  C12N9/14 ,  A61K47/6917 ,  C07K14/75 ,  C07K2319/01 ,  C07K2319/035 ,  C07K2319/055 ,  C07K2319/30 ,  C07K2319/74 ,  C07K2319/75 ,  C07K2319/912 ,  C07K2319/915 ,  A61K38/00

摘要： Described herein are compositions and techniques related to generation and therapeutic application of artificial synapses. Artificial synapses are engineered extracellular vesicles, including exosomes, which incorporate sticky binders on their surface to anchor signaling domains against biological targets, such as receptors. These engineered additives can be organized in genetic vector constructs, expressed in mammalian cells, wherein the sticky binders attach to extracellular vesicles such as exosomes, thereby presenting their joined signaling domains which are rapidly taken up by recipient cells. Artificial synapses adopt the hallmark biophysical and biochemical features of extracellular vesicles, allowing for rapid deployment and scale-up. Importantly, this strategy can allow for kinetically favorable signal generation and signal propagation. This includes, for example, increasing density of agonist presentation to support receptor clustering—an onerous barrier for traditional receptor targeting strategies.

公开(公告)号：US11746138B2

公开(公告)日：2023-09-05

申请号：US17377520

申请日：2021-07-16

申请人： DIADEM BIOTHERAPEUTICS INC.

发明人： Mickey Pentecost ,  Wojciech Bartkowski

IPC分类号： C07K14/705 ,  A61K47/69 ,  A61K47/58 ,  A61K47/62 ,  A61K47/54 ,  A61P27/02 ,  A61P37/06 ,  C12N9/14 ,  C07K14/75 ,  A61K38/00

CPC分类号： C07K14/70532 ,  A61K47/544 ,  A61K47/605 ,  A61K47/62 ,  A61K47/69 ,  A61K47/6901 ,  A61K47/6911 ,  A61K47/6917 ,  A61P27/02 ,  A61P37/06 ,  C07K14/705 ,  C07K14/7056 ,  C07K14/70521 ,  C07K14/70596 ,  C07K14/75 ,  C12N9/14 ,  A61K38/00 ,  C07K14/70503 ,  C07K2319/01 ,  C07K2319/02 ,  C07K2319/035 ,  C07K2319/055 ,  C07K2319/30 ,  C07K2319/74 ,  C07K2319/75 ,  C07K2319/912 ,  C07K2319/915 ,  C12Y304/24081

摘要： Described herein are compositions and techniques related to generation and therapeutic application of artificial synapses. Artificial synapses are engineered extracellular vesicles, including exosomes, which incorporate sticky binders on their surface to anchor signaling domains against biological targets, such as receptors. These engineered additives can be organized in genetic vector constructs, expressed in mammalian cells, wherein the sticky binders attach to extracellular vesicles such as exosomes, thereby presenting their joined signaling domains which are rapidly taken up by recipient cells. Artificial synapses adopt the hallmark biophysical and biochemical features of extracellular vesicles, allowing for rapid deployment and scale-up. Importantly, this strategy can allow for kinetically favorable signal generation and signal propagation. This includes, for example, increasing density of agonist presentation to support receptor clustering an onerous barrier for traditional receptor targeting strategies.

公开(公告)号：US20230266327A1

公开(公告)日：2023-08-24

申请号：US18188958

申请日：2023-03-23

申请人： Cizzle Biotechnology Limited

发明人： Dawn Alison COVERLEY

IPC分类号： G01N33/574 ,  C07K14/75 ,  C12N9/26 ,  A21D8/04 ,  A61K38/36 ,  G01N33/50

CPC分类号： G01N33/57423 ,  C07K14/75 ,  G01N33/574 ,  C12Y302/01133 ,  C12N9/2414 ,  A21D8/04 ,  A61K38/363 ,  G01N33/5076

摘要： The present invention relates to the use of a fibrinogen capture agent or a fibrinogen detection agent in an assay to detect a Ciz1 b-variant.

公开(公告)号：US20230183320A1

公开(公告)日：2023-06-15

申请号：US17801907

申请日：2021-02-24

申请人： ST. JUDE CHILDREN’S RESEARCH HOSPITAL, INC.

发明人： Fabio DEMONTIS ,  Liam HUNT ,  Flavia GRACA ,  Mamta RAI

IPC分类号： C07K14/75 ,  C12N15/63 ,  A61K38/36 ,  A61P21/00

CPC分类号： C07K14/75 ,  A61K38/363 ,  A61P21/00 ,  C12N15/63 ,  C07K2319/43

摘要： Recombinant Fibrinogen C Domain Containing 1 (rFibcd1) proteins and methods for using the same in the treatment of muscle atrophy are provided as are vectors, host cells, pharmaceutical compositions and modified RNA molecules encoding the rFibcd1 proteins.

公开(公告)号：US11667694B2

公开(公告)日：2023-06-06

申请号：US17212738

申请日：2021-03-25

申请人： FIBRIANT B.V.

发明人： Miranda Weggeman ,  Joseph Grimbergen ,  Jacob Koopman

IPC分类号： A61K38/00 ,  C07K14/75 ,  A61P31/04 ,  A61K9/00 ,  A61K45/06

CPC分类号： C07K14/75 ,  A61P31/04 ,  A61K9/0019 ,  A61K38/00 ,  A61K45/06

摘要： The present invention relates to compositions comprising fibrinogen gamma prime variants for use in the treatment or prevention of an infection and methods of administering the composition. The fibrinogen gamma prime variants in the composition comprise at least one fibrinogen gamma prime polypeptide chain. The compositions for use according to the invention may also comprise other fibrinogen variants. Compositions comprising fibrinogen gamma prime variants according to the invention improve survival time after infection up to more than 200 percent compared to WT fibrinogen. They may be used both therapeutically and prophylactically.

公开(公告)号：US11634473B2

公开(公告)日：2023-04-25

申请号：US16814088

申请日：2020-03-10

申请人： Omrix Biopharmaceuticals Ltd. ,  Ethicon, Inc.

发明人： Erez Ilan ,  Kfir Regev ,  Dana Leitman ,  Israel Nur ,  Moti Meron ,  John Goodman

IPC分类号： C07K14/75 ,  A61M5/19 ,  A61M5/28 ,  B01F23/50 ,  B01F25/451 ,  B01F33/25 ,  B01F33/501 ,  B01F35/71

摘要： Provided are methods and devices for dissolving solid protein compositions, such as solid compositions comprising fibrinogen, in an aqueous solvent. The methods comprise use of a closed container containing a volume of solid fibrinogen composition and a head space wherein the pressure within the headspace is sub-atmospheric. Aqueous solvent is introduced into the container while maintain the sub-atmospheric pressure, and subsequent to addition of the solvent, the size of the headspace is decreased to bring the pressure to atmospheric pressure. The devices are suitable for use in the disclosed method.